BNP/CALL/ELI LILLY & CO/1000/0.1/20.12.24 | Market Closed - Boerse Frankfurt Warrants 01:20:25 18/05/2024 am IST | ||
| 1.73 EUR | -2.81% |
|
| Current month | -16.67% | ||
| 1 month | -14.22% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 17/24/17 | 1.75 | -1.69% |
| 16/24/16 | 1.78 | -9.64% |
| 15/24/15 | 1.97 | +23.12% |
| 14/24/14 | 1.6 | +4.58% |
| 13/24/13 | 1.53 | -5.56% |
Real-time Boerse Frankfurt Warrants
Last update May 18, 2024 at 01:20 am IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PC5FBJ |
| ISIN | DE000PC5FBJ5 |
| Date issued | 21/02/2024 |
| Strike | 1,000 $ |
| Maturity | 20/12/2024 (215 Days) |
| Parity | 10 : 1 |
| Emission price | 2.93 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.71 € |
|---|---|
| Lowest since issue | 1.18 € |
| Spread | 0.02 € |
| Spread % | 1.14% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
770
USD
Average target price
850.4
USD
Spread / Average Target
+10.44%
- Stock Market
- Warrants
- Warrant
